Skip to navigation Skip to main contented Skip to close file
TipRanks
Tue, March 10, 2026 astatine 9:00 AM CDT 1 min read
Greenridge expert William Gregozeski lowered the firm’s price target connected EUDA Health (EUDA) to $2.75 from $6 and keeps a Buy standing connected the shares. The steadfast updated its exemplary for a simplification of Helixe bottles sold successful 2026, decreasing to 50,000 from 105,000, which reduced its gross estimation to $27.23M from $43.05M. It besides added successful the 12.5M shares that were issued successful precocious February, which had a dilutive effect connected its EPS estimates, the expert tells investors.
-
Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
-
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential
Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>
See Insiders’ Hot Stocks connected TipRanks >>
Read More connected EUDA:
Disclaimer & DisclosureReport an Issue
-
EUDA Health Repurchases Streeterville Warrant and Amends Charter to Clarify Share Actions
-
EUDA Health announces repurchase, cancellation of Streeterville warrant
-
EUDA Health Raises $3.75 Million and Retires Dilutive Warrant successful February 2026 Capital Moves
-
EUDA Health Lowers Streeterville Warrant Exercise Price to Align With Market Conditions
-
EUDA Health announces 2nd amendment to Streeterville warrant agreement

1 hour ago
1





English (CA) ·
English (US) ·
Spanish (MX) ·